Primary pulmonary hypertension: Update on pathogenesis and novel therapies

Cleveland Clinic Journal of Medicine

Volumn 67, Issue 3, 2000, Pages 175-190

  Arroliga, Alejandro C ^a   Dweik, Raed A ^a   Kaneko, F J Takao ^b   Erzurum, Serpil C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Military Hospital Centre   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; VASODILATOR AGENT;

HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; PATIENT EDUCATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SURVIVAL RATE; THROMBOSIS; TREATMENT PLANNING;

EID: 0034094847     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.67.3.175     Document Type: Review

References (50)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1998; 336:111-117.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107:216-223.
3. Elliott G, Alexander G, Leppert M. Yeates S, Kerber R. Coancestry in apparently sporadic primary pulmonary hypertension. Chest 1995; 108:975-977.
4. Nichols WC Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nature Genetics 1997; 15:277-280.
5. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 2603-2606.
6. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective study. Ann Intern Med 1991; 115:343-349.
7. Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: Clinical characterization and survival. J Am Coll Cardiol 1995; 25:466-474.
8. Olivari Maria-Teresa. Primary pulmonary hypertension. Am J Med Sci 1991; 302:185-198.
9. Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension. Clinical picture and surgical treatment. Eur Respir J 1992; 5:334-342.
10. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (Epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997; 1479-1486.
11. Gorcsan J III, Edwards TD, Ziady GM, Katz WE, Griffith BP. Transesophageal echocardiography to evaluate patients with severe pulmonary hypertension for lung transplantation. Ann Thorac Surg 1995; 59:717-722.
12. Fernandez-Bonetti P, Lupi- Herrera E, Martinez-Guerra ML, Barrios R, Seoane M, Sandoval J. Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). Chest 1983; 83:732-738.
13. O'Hagan AR, Stillwell PC, Arroliga AC. Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension. Clin Pediatric 1999; 38:27-33.
14. Robalino BD, Moodie DS. Primary pulmonary hypertension, then and now: 28 years of experience. Cleve Clin J Med 1992; 59:411-417.
15. Isern RA, Yaneva M, Weiner E, et al. Autoantibodies in patients with primary pulmonary hypertension: Association with anti-Ku. Am J Med 1992; 93:307-312.
16. Natens M, Freels S, Kaufmann E, Yvy PS, Rich S. Timing of single lung transplantation for primary pulmonary hypertension. J Heart Lung Transplant 1994; 13:276-281.
17. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
18. Schrader BJ, Inbar S, Kaufman L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19:1060-1064.
19. Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997; 52:369-372.
20. Channick RN, Newhart JW, Johnson FW et al. Pulse delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. Chest 1996; 109:1545-1549.
21. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665.
22. Magnanl B, Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996; 17:18-24.
23. Higenbottam TW, Wheeldon D, Wells FC, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1:1046-1047.
24. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301.
25. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343-349.
26. McLaughlin W, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-277.
27. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-824.
28. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect on a new oral PGI2 analogue, beraprost, in primary pulmonary and secondary pulmonary hypertension. Am J Cardiol 1996; 78:244-247.
29. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension [letter]. Lancet 1997; 349:1365.
30. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70:580-587.
31. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714-721.
32. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31:1650-1657
33. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe pulmonary hypertension. J Am Coll Cardiol 1998; 32:297-304.
34. Kerstein D, Levy PS, Hsu DT, Hordorf AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91:2028-2035.
35. Gaine SP, Rubin LJ. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci 1998; 315:179-184.
36. Maurer JR, Frost AE, Glanville AR, Estenne M, Higenbottam T. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998; 158:335-339.
37. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114:464-469.
38. Giaid A, Ynagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
39. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75.
40. Adnor S, Raffestin B. Pulmonary hypertension: NO therapy? Thorax 1996; 51:762-764.
41. Loscalzo J. Nitric oxide and vascular disease [editorial]. N Engl J Med 1995; 333:251-253.
42. Stamler JS, Loh E, Rody MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89:2035-2040.
43. Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996; 93:266-271.
44. Voelkel NF, Hoeper M, Maloney J, Tuder RM. Vascular endothelial growth factor in pulmonary hypertension. Ann NY Acad Sci 1996; 796:186-193.
45. Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:917-923.
46. Stenmark KR, Mecham RP. Cellular and molecular mechanism of pulmonary vascular remodeling. Annu Rev Physiol 1997; 59:89-144.
47. Schuster DP, Crouch EC, Parks WC, Johnson T, Botney MD. Angiotensin converting enzyme expression in primary pulmonary hypertension. Am J Respir Crit Care Med 1996; 154:1087-1091.
48. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-254.
49. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996; 9:356-363.
50. Cacoub P, Karmochkine M, Dorent R, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996; 101:160-164.